Clinical Trial
Study Details
Administered as an IV infusion
This is a phase 1, first-in-human, multi-center, open-label, single dose cohort study to evaluate the safety and tolerability, pharmacokinetics (PK), exploratory pharmacodynamics (PD), and biomarkers of target engagement of CSL889 following single intravenous (IV) doses in subjects with sickle cell disease (SCD). The study involves sequential dose escalation of cohorts with between-group assessments of key safety and PK variables.
Study Overview
Contacts and Locations
University of Illinois Hospital and Health Science Systems
Chicago, Illinois 60612
United States
The Johns Hopkins Hospital
Baltimore, Maryland 21287
United States
University of Minnesota
Minneapolis, Minnesota 55455
United States
Jacobi Medical Center
The Bronx, New York 10461
United States
Brody School of Medicine at East Carolina University
Greenville, North Carolina 27834
United States
Ohio State University
Columbus, Ohio 43201
United States
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania 15232
United States
Medical University of South Carolina
Charleston, South Carolina 29425
United States
Amsterdam UMC Academic Medical Center
Amsterdam
Netherlands
Erasmus University Medical Center
Rotterdam
Netherlands
Liverpool University Hospital
Liverpool
United Kingdom
Guys and St. Thomas
London
United Kingdom
University College London Hospital
London
United Kingdom
Manchester University Hospitals NHS Foundation Trust / Manchester Royal Infirmary
Manchester
M13 9WL
United Kingdom
Early Phase Unit
Manchester
United Kingdom